SJM:NYSEThe J.M. Smucker Company Analysis
Data as of 2026-06-05 - not real-time
$101.12
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The J. M. Smucker Company is trading at $101.12, just below its 20‑day SMA of 101.43 and above the 50‑day SMA of 97.66, indicating a flat short‑term trend. RSI sits at 52, suggesting neither overbought nor oversold conditions, while the MACD histogram is negative (‑0.26) and the signal line is bearish, pointing to modest downside pressure. Volatility is elevated at 21.6% over the past 30 days, yet beta is near zero (‑0.09), reflecting limited market‑wide sensitivity. The DCF‑derived fair value of $77.30 is well below the current price, flagging the stock as overvalued by roughly 14%, despite a forward PE of 10.33 and an attractive 4.35% dividend yield. Analyst consensus remains bullish with a “buy” recommendation and a median target of $120, implying upside potential if earnings improve.
Fundamentally, revenue grew 7% YoY to $8.93 B, but profit margins remain negative (‑14%) and ROE is –20.7%, underscoring profitability challenges. The company generates solid operating cash flow ($1.29 B) and free cash flow ($0.88 B), yet carries $7.5 B of debt, resulting in a debt‑to‑equity ratio of 143%, which pressures dividend sustainability given an 86% payout ratio. Recent news of a strategic portfolio review by Goldman Sachs and an upcoming earnings release suggest management is seeking growth catalysts, but the high debt load and weak earnings raise questions about long‑term dividend resilience.
Fundamentally, revenue grew 7% YoY to $8.93 B, but profit margins remain negative (‑14%) and ROE is –20.7%, underscoring profitability challenges. The company generates solid operating cash flow ($1.29 B) and free cash flow ($0.88 B), yet carries $7.5 B of debt, resulting in a debt‑to‑equity ratio of 143%, which pressures dividend sustainability given an 86% payout ratio. Recent news of a strategic portfolio review by Goldman Sachs and an upcoming earnings release suggest management is seeking growth catalysts, but the high debt load and weak earnings raise questions about long‑term dividend resilience.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering near short‑term support at $95.71
- Bearish MACD histogram indicating limited upside
- Decreasing volume suggesting waning buying interest
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward EPS upside and positive earnings outlook
- Strong 4.35% dividend yield attractive to income investors
- Analyst consensus buy and median price target of $120
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High debt‑to‑equity ratio (143%) limiting financial flexibility
- Negative profitability metrics (profit margin, ROE)
- Valuation gap between market price and DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth7.00%
Profit Margin-14.07%
P/E Ratio10.3
ROE-20.68%
ROA4.80%
Debt/Equity143.20
P/B Ratio2.1
Op. Cash Flow$1.3B
Free Cash Flow$884.5M
Technical Analysis
TrendNeutral
RSI52.1
Support$95.71
Resistance$104.81
MA 20$101.43
MA 50$97.66
MA 200$103.45
MACDBearish
VolumeDecreasing
Fear & Greed Index92.98
Valuation
Fair Value$77.31
Target Price$115.35
Upside/Downside14.08%
GradeOvervalued
TypeValue
Dividend Yield4.35%
Risk Assessment
Beta-0.09
Volatility21.58%
Sector RiskLow
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.